Potential value of ctDNA monitoring in metastatic HR + /HER2 - breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial.
Joanne ChiuFei SuMukta JoshiNorikazu MasudaTakashi IshikawaTomoyuki ArugaJuan Pablo ZarateNaveen BabbarO Alejandro BalbinYoon Sim YapPublished in: BMC medicine (2023)
ClinicalTrials.gov NCT02333370 . Registered on January 7, 2015.